NewYorkBIO thanks our Sustaining Members
Notes from Nathan
NewYorkBIO applauds both the Governor's and Mayor's economic development initiatives, and we are particularly proud that both proposals include elements for which NewYorkBIO has long advocated: substantial capital investment in facilities for growth-stage companies is key to our industry's growth in New York; refundable tax credits for small companies will help more of our members stay here and take root; and targeted support for a scientific talent development will ensure that New York not only trains the best-prepared life science professionals, but keeps them here, too.
While New York life science seems to be a daily media focus of late, not all of that focus is necessarily positive. And even though we strongly support these economic development initiatives and investments, we are concerned about the mixed signals that politicians are sending to the industry. We are particularly concerned by proposed legislation that seems to punish successful companies for bringing products to patients by limiting their ability to recoup the massive investments required for drug development. This, in turn, suppresses innovation and casts a chill over investment. To learn more, read our Memoranda on the Public Policy page of our website.
These issues are at the heart of our industry, and they will help determine whether New York does indeed grow a vibrant, international biotech presence that makes Massachusetts worry. In March, NewYorkBIO members will gather for
New York Bioscience Advocacy Day and Legislative Fly-In
in Albany, where we will meet to press our case for industry support. The Federal version, BIO Fly-In, will be held April 4th and 5th, so save the date. Because these issues are so important to our industry, these advocacy events that are free of charge and open to all, whether members of NewYorkBIO or not.
New York life sciences certainly are at a tipping point, and NewYorkBIO members should use this opportunity to make their voices heard.
I look forward to seeing you there.
News for New York out of JP Morgan 2017
The JP Morgan Investor Conference serves as the kick-off to the new financial year, and, despite being hit by San Francisco's Storm of the Century, the 2017 conference broke several big stories
of interest to the New York life sciences community.
In a major development for New York, Johnson & Johnson Innovation announced that it was opening JLABS @ NYC in collaboration with New York State and the New York Genome Center. NewYorkBIO's Nathan Tinker said, "JLABS @ NYC adds another major research asset to New YorkCity's increasingly impressive number of commercial research centers." Set to open in 2018 at the New York Genome Center, JLABS's proposed 30,000 square foot facility joins commercial research centers, such as the Pfizer Center for Therapeutic Innovation and the Roche Translational Research Center as well as renowned academic research centers making a home in New York.
In addition to the J&J Innovation announcement, the big stories of the JP Morgan conference centered on mergers and acquisitions, which should generate, Tinker said, a dynamic climate for New York's growth companies.
NewYorkBIO to Partner BIO CEO & Investor Conference 2017
As the premier east coast conference for publicly traded life science companies, the BIO CEO & Investor Conference looks to generate a strong
at the Waldorf Hotel on February 13th and 14th. NewYorkBIO Executive Director Nathan Tinker said that, as local co-host, the organization is "proud to
partner with BIO in producing this important conference, and we are, once
again, welcoming attendees with our rooftop reception on Sunday evening
Attracting life science companies and investors from across the industry, the BIO CEO & Investor Conference is set to include panel sessions, Fireside Chats, and partnering opportunities. Anticipated topics include microbiome research applications, next-generation pain control, biosimilars, and a policy outlook for the new administration. Last year's conference attracted 1400 attendees, including approximately 650 investors, and generated 2,500 partnering meetings and 190 company presentations. NewYorkBIO will host a welcome reception on Sunday, February 12th.
New York Legislative Update
NEW YORK CITY AND STATE
The budget provisions announced in December and January, including b
oth the state and city life science economic development initiatives, are moving through the legislative process. NewYorkBIO is actively engaging with both the City and the State to advocate for our membership's
Governor Cuomo's $650 million state-wide life science economic development program
focuses on development and investment in commercial life science across New York State.
NewYorkBIO welcomes important provisions of the governor's initiative:
- Addressing the lack of affordable lab space, including designating tax-free zones under the StartUP NY program as well as funding for the creation of new life science incubators in the state. NewYorkBIO also supports a restructuring of the StartUP NY program make it easier for companies to find tax-free space and to aid in the development of life science clusters tied to institutions of higher learning.
Increasing access to capital for early and growth-stage companies, including a refundable corporate tax credit to help early stage companies access capital. NewYorkBIO applauds this position and encourages the state to revisit the refund ability of other existing tax credits for early and growth stage companies.
- Attracting and retaining top scientific talent, including the implementation of a life sciences researcher recruitment program. NewYorkBIO remains committed to creating opportunities to increase the connectivity of our industry.
NYC Mayor Bill de Blasio's proposal aims to deliver a total investment of more than $500 Million to New York City's life science sector over the next 10-25 years with the goal of creating 16,000 jobs for New Yorkers.
NewYorkBIO applauds the Mayor's
program to strengthen the life sciences ecosystem in NYC through strategic initiatives and public-private partnerships in key areas:
- Spurring the creation of additional commercial lab space in New York, with targeted tax incentives as well as direct investment to fund incubators and innovation centers. NewYorkBIO strongly feels that these provisions will help offset the high cost of built-out lab space, while at the same time encouraging co-location among companies and among companies with academic partners.
- Developing a pipeline for academic talent, both by attracting talent to New York and by cultivating it through our world class academic institutions. Employ New Yorkers
- Building a Life Sciences Management Corps and the Mayor's Life Sciences Advisory Council. NewYorkBio encourages the groups to investigate how smaller companies may begin to pool some shared services to compete effectively for talent.
NewYorkBIO has been advocating for this kind of large-scale thinking and investment, and we applaud the vision put forth by both
Governor Cuomo and Mayor de Blasio to grow this vital industry.
Nathan Tinker, NewYorkBIO Executive Director said of the initiatives, "New York is truly poised to build the world's foremost life science cluster, with a range of business, research, and patient assets unavailable anywhere else. NewYorkBIO has a wide array of experts within our membership who are enthusiastic about these opportunities to strengthen our industry while helping the next generation of innovators to succeed. We look forward to to working with the governor, the mayor, and their administrations to make New York the premiere destination for life sciences innovation and research."
For more information:
NEW YORK STATE
NewYorkBIO Opposes Effort to Mandate Price Controls on Biopharmaceutical Products
NewYorkBIO strongly opposes Part D of the Health and Mental Hygiene Article VII budget proposal. This
proposal would allow the state to impose draconian price controls on all pharmaceuticals sold in New York and
thereby disincentivize innovative drug makers from offering their products in the New York market. Most
importantly, it would stifle the development of innovative therapies that target some of the most challenging and
debilitating diseases in our lifetime.
NewYorkBIO To Host New York Bioscience Advocacy Day
Once a year, NewYorkBIO hosts Bioscience Advocacy Day, inviting life science and health executives from across New York to come to Albany for a day of legislative briefings and advocacy.
For 2017, NewYorkBIO will host delegations in one-on-one and small group meetings with legislators, agencies, and departments on
March 6-7, 2017.
We look forward to another great day of engaging with Members of the State Legislature and their senior staff on the most important legislative issues facing the biotechnology industry in New York, including fair pricing, economic development, and patient access to innovative therapies.
NewYorkBIO will schedule all legislative meetings and provide attendees with a legislative briefing prior to their visits to the Statehouse. Attendees meet in small groups with legislators, agencies, key offices and committees, and senior staff. Each group will be accompanied by a NewYorkBIO staff representative for all visits.
Because these issues are so important to the bioscience community, there is no registration fee for members or non-members to attend Bioscience Advocacy Day.
It is always our goal to make the Bioscience Advocacy Day as easy as possible for our visiting attendees; please do not hesitate to contact us with questions.
NewYorkBIO will Lead Delegation To BIO Legislative Fly-In, Washington DC
On April 4 and 5, 2017, NewYorkBIO will lead the New York delegation for t
he BIO Legislative Day Fly-In. The Fly-In is a free event hosted by BIO as a benefit of membership. Attendees are invited to participate in a legislative briefing and networking reception on Tuesday, April 4. On Wednesday April 5 attendees will visit congressional offices and participate in meetings with New York senators, representatives, and staff. Likely topics for discussion include ACA reform, FDA reform, the regulatory landscape, and patent reform.
Quarterly Board of Directors Meeting
2017 New York Bioscience Advocacy Day and Legislative Fly-in
Wednesday, May 10, 2017
2017 NewYorkBIO Annual Conference
NewYorkBIO is proud to be the Local Co-Host of the BIO CEO & Investor Conference.
Registration is now open for the
BIO CEO & Investor Conference
, one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.
Complimentary registration is available for qualified investors.
NewYorkBIO members receive a special discounted registration:
Early registration: $2,050
Late registration: $2,250
Use registration code: BIOCEO11
Welcome New Members
Applied Biological Laboratories Inc.
Center For Aquatic Animal Research and Management
New York, NY
Garwood Medical Devices, LLC
Klus Pharma Inc. Biologics
Longfellow Real Estate Partners, LLC
New York, NY
Mosaica Therapeutics Inc.
Howard Beach, NY
New York, NY
Raadysan Biotech Inc.
SCINSPIRE Holding & Consulting GmbH
New York, NY
New York , NY
New York, NY
|NewYorkBIO Member News
If you have news to share with our 20,000+ subscribers, please send notes or releases to
AbbVie announced that the U.S. Food and Drug Administration approved IMBRUVICA® (ibrutinib) for the treatment of patients with relapsed/refractory marginal zone lymphoma who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Accelerator Corporation is included in a Forbes story about its backing of Petra Pharma, a New York City startup with several members of NewYorkBIO as investors.
Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals announced that Dr. Mark Berger has been appointed Chief Medical Officer.
Albert Einstein College of Medicine
Einstein and Montefiore are key members of an international consortium of academic research institutions that have been awarded a $21 million grant from the National Institutes of Health (NIH) to develop better ways to prevent the development of epilepsy following traumatic brain injuries.
Alexandria Center/Alexandria Real Estate
The developer of the Alexandria Center for Life Science is opening an incubator at the property for startups in the medical and pharmaceutical fields.
Argon Medical Devices Biocoatings Corp.
Argon Medical Devices, Inc., announced the completed acquisition of three vascular products from Rex Medical, LLC.
Astellas Pharma US
BioHealthWays, Inc., was accepted into SUNY Downstate Medical Center's Incubator program.
Bristol Myers Squibb
BMS and GeneCentric Diagnostics, Inc., announced a biomarker research collaboration.
Cellectis, Inc., announced that four new members joined Cellectis' Clinical Advisory Board.
Celmatix launched its screening test for women's fertility.
City University of New York
CUNY Biomedical Engineering announced that NIH-NINDS awarded a 5-year R01 grant for its investigational work entitled, "Effects of direct-current stimulation on synaptic plasticity."
Columbia University Medical Center
Lin Bioscience and Columbia Technology Ventures announced that Lin Bioscience has licensed the intellectual property portfolio and development program for a medication intended to slow or halt the progression of atrophic "Dry" Age-Related Macular Degeneration.
Conner Strong & Buckelew (NewYorkBIO Sustaining Member)
Conner Strong & Buckelew has launched BeneCare.
ContraFect announced that it has entered into a three year collaborative research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria.
Efferent Labs announced that it has entered into a multi-year agreement with Evotec
AG, for the continued development of Efferent's CytoComm™ Living Biosensor System.
Eli Lilly and Company
Eli Lilly and Company announced the expansion of an existing immuno-oncology collaboration with Merck to add a new study of Lilly's LARTRUVO™ (olaratumab) with KEYTRUDA® (pembrolizumab) in patients with previously treated advanced or metastatic soft tissue sarcoma (STS).
Fox Rothschild LLP
Christopher P. Beall, Perla M. Kuhn, Michael Leonard, Barbara Grahn, David I. Greenbaum and Christopher D. Olszyk Jr. were featured in the 2017 WTR 1000 list.
Frommer Lawrence & Haug, LLP (NewYorkBIO Sustaining Member)
Frommer Lawrence & Haug has been chosen the Healthcare and Life Sciences Award winners of 2016 by Corporate Livewire.
Genentech announced that the U.S. Food and Drug Administration has approved Lucentis® 0.5 mg for the treatment of patients with myopic choroidal neovascularization.
HHMI/The Rockefeller University
Elaine Fuchs, Rebecca C. Lancefield Professor and head of the Robin Chemers Neurstein Laboratory of Mammalian Cell Biology and Development, and a Howard Hughes Medical Institute investigator, has been honored with the 2017 McEwen Award for Innovation, given by the International Society for Stem Cell Research.
iCell Gene Therapeutics
iCell Gene Therapeutics announced the publication of its preclinical CD4CAR T-cell data in Leukemia, a leading hematology-oncology journal.
Johnson & Johnson Innovation, LLC (NewYorkBIO Sustaining Member)
Johnson & Johnson Innovation LLC, New York State, and the New York Genome Center announced a collaboration to launch a new JLABS in New York City.
Merck & Co Inc.
Merck Inc. announced that the FDA has accepted for review the supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) plus chemotherapy for the first-line treatment of patients with metastatic or advanced non-squamous non-small cell lung cancer.
Mirimus, Inc. and Charles River Laboratories International, Inc., together expand their mouse engineering capabilities through a strategic partnership.
New York Blood Center, Inc.
New York Blood Center announced that researcher Dr. Sara Lustigman, Head of the Laboratory of Molecular Parasitology at NYBC's Lindsley F. Kimball Research Institute, led the first-ever effort to generate a high-quality genome assembly of Onchocerca volvulus, the filarial parasite that causes onchocerciasis, also known as river blindness.
New York Genome Center
Johnson & Johnson Innovation LLC, New York State, and the New York Genome Center announced a collaboration to launch a new JLABS in New York City.
New York Medical College
BioInc@NYMC hosted a grand opening ribbon cutting event on December 6 to welcome its anchor client, Philips Healthcare Research.
New York Stem Cell Foundation
A collaboration beginning in 2013 between the NYSCF Research Institute and the Personal Genome Project (PGP) resulted in the availability of a unique new stem cell resource for scientists around the world.
A study led by researchers from NYU Langone Medical Center and Memorial Sloan Kettering Cancer Center, and published online January 25 in Science Translational Medicine, offers potential new way to target stem cell-driven blood cancers.
Optologix LLC announced publication of a study featuring TAEL, the zebrafish LITE Switch System, in the journal
Roche, Inc., announced that the U.S. Food and Drug Administration has accepted the company's supplemental Biologics License Application and granted Priority Review for TECENTRIQ® (atezolizumab)
esearchers at The Rockefeller University have developed an automated technology that combines imaging with digital analysis and machine learning to help physicians detect melanoma at its early stages.
SUNY Downstate Medical Center
The State University of New York Board of Trustees has appointed Wayne J. Riley, MD, MPH, MBA, MACP, as president of SUNY Downstate Medical Center.
Syndax Pharmaceuticals, Inc.
Syntax Pharmaceuticals, Inc., announced that it has entered into a Cooperative Research and Development Agreement
with the National Cancer Institute for intramural preclinical and
Synthetic Genomics, Inc., announced that it has entered a research and licensing option agreement with Janssen Vaccines & Prevention B.V., to apply Synthetic Genomics' proprietary replicon RNA technology toward the design and development of novel RNA-based medicines for specific infectious diseases. The deal was facilitated by Johnson & Johnson Innovation.
Versant Ventures announced several Investment Team appointments in preparation for the launch of its newest fund.
Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals, Inc., announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising research and development programs that represent novel approaches to the treatment of cancer.
Weill Cornell Graduate School of Medical Sciences
Weill Cornell Graduate School of Medicine announced a foundational gift that will launch the Ellen and Gary Davis Immune Monitoring Core, a critical research infrastructure that will serve as a repository for patient tumor samples, genomic sequencing and bioinformatics.
NewYorkBIO members get the best deals on the products they use every day:
Through our partnership with BIO, NewYorkBIO is proud to offer a new program with UPS to bring
members up to 70% off UPS Next Day Air® services, and up to 65% off UPS Worldwide International
This is a significant savings off published rates! UPS offers members great savings, and the
peace of mind that accompanies reliable service with guaranteed delivery, and innovative technology.
Members currently enrolled in the expired FedEx program can expect to see additional savings of 10%-
20% by switching to UPS.
Existing UPS customers must enroll to take advantage of this exclusive offer.
The special pricing and benefits offered by UPS to members through this program include:
- Save from 50-70% on UPS Next Day Air® services
- Save from 30-55% on UPS 2nd Day Air® services
- Save from 35-55% on UPS 3 Day Select Services®
- Save from to 18- 47% on UPS Ground® Commercial services
- Save from to 12-40% on UPS Ground® Residential services
- Save up to 65% on UPS Worldwide International services
Additional Member Benefits
- Special pricing on UPS' Proactive Response
- UPS Capital Flexible Parcel Insurance
- UPS Temperature True® Packaging
- UPS Store Business Services discounts and other Value added services